SAENGER BRADLEY 4
4 · Tonix Pharmaceuticals Holding Corp. · Filed Feb 27, 2025
Insider Transaction Report
Form 4
SAENGER BRADLEY
Chief Financial Officer
Transactions
- Award
Stock Option
2025-02-25+25,792→ 25,792 totalExercise: $8.05From: 2026-02-25Exp: 2035-02-25→ Common Stock (25,792 underlying) - Other
Common Stock, par value $0.001
2025-02-05−0.04→ 0 total - Award
Stock Option
2025-02-25+25,792→ 25,792 totalExercise: $10.06From: 2026-02-25Exp: 2035-02-25→ Common Stock (25,792 underlying)
Footnotes (3)
- [F1]Shares were surrendered without considerations following a reverse stock split of the Issuer's common stock.
- [F2]One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
- [F3]The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.